title: Use of recombinant factor VIIa in infants with severe coagulopathy.
abstract: The risk of hemorrhage in infants with severe coagulopathies unresponsive to fresh frozen plasma (FFP) infusions may preclude therapeutic invasive interventional procedures. We describe the successful use of recombinant factor VIIa (rFVIIa) in two such infants, the first with cirrhosis requiring paracentesis and the second with necrotizing enterocolitis requiring laparotomy. This report reviews the current concepts on the mechanism of action of the drug rFVIIa and considers its expanded use in infants unresponsive to FFP replacement.
authors.affiliation: Department of Pathology, Transfusion Medicine Division, Medical University of South Carolina, Stanford University, Stanford, CA 94305-5626, USA. magalif@stanford.edu
authors.forename: Magali J
authors.initials: MJ
authors.lastname: Fontaine
authors.forename: John
authors.initials: J
authors.lastname: Lazarchick
authors.forename: Sarah
authors.initials: S
authors.lastname: Taylor
authors.forename: David
authors.initials: D
authors.lastname: Annibale
mesh_terms: D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa